

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Amyloidosis | D000686 | EFO_1001875 | E85 | 1 | 3 | 1 | — | — | 5 |
| Familial amyloid neuropathies | D028227 | — | E85.1 | — | 1 | 1 | — | — | 2 |
| Amyloid neuropathies | D017772 | — | — | — | 1 | 1 | — | — | 2 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | 1 | — | — | 1 |
| Familial amyloidosis | D028226 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Polyneuropathies | D011115 | EFO_0009562 | A69.22 | — | 1 | — | — | — | 1 |
| Drug common name | Revusiran |
| INN | revusiran |
| Description | Revusiran is an oligonucleotide pharmaceutical. It is currently being investigated in clinical studies. |
| Classification | Oligonucleotide |
| Drug class | — |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | — |
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594492 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | ZE6EHM8Z3A (ChemIDplus, GSRS) |
